[Pubmed] An update on the use of immunoglobulins as treatment for myasthenia gravis
Posté : 31 mai 2022 12:00
Expert Rev Clin Immunol. 2022 May 31. doi: 10.1080/1744666X.2022.2084074. Online ahead of print.
ABSTRACT
INTRODUCTION: Myasthenia gravis (MG) is an antibody mediated disease where pathogenic antibodies interact with the acetylcholine receptor or other proteins at the post-synaptic neuromuscular junction. There is growing evidence that immunoglobulin infusions are beneficial for clinical exacerbations and chronic refractory disease and may be an option for patients unresponsive to conventional immunosuppressive therapies.
AREAS COVERED: We performed an extensive literature review, looking for evidence on the use of immunoglobulins for the treatment of MG, by conducting a search in MEDLINE (1946 to present), EMBASE (1947 to present) and Clinicaltrials.gov. We have included studies on the use of intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) for acute deterioration and chronic disease.
EXPERT OPINION: The use of IVIG in MG provides an option for rapid improvement in critical deterioration, being preferred over more invasive and less available therapies such as plasmapheresis. For refractory MG, the addition of IVIG can improve a patient's status and reduce the dosage of immunosuppressive medications. The alternative of SCIG is also effective and has advantages of infusion time flexibility, fewer side-effects, and patient independence. The safety and efficacy of both interventions, patient preferences and quality of life may direct therapeutic choices in the future.
PMID:35639497 | DOI:10.1080/1744666X.2022.2084074
Source: https://pubmed.ncbi.nlm.nih.gov/3563949 ... 1&v=2.17.6